The programme was developed to present to both clinicians and researchers the most up-to-date information on hereditary breast and ovarian cancer.

Upon completion of the programme the learner will be able to:

  • Better and more efficiently identify individuals who are at high risk for hereditary cancer;
  • Review the latest developments in the genetics and molecular science of hereditary breast and ovarian cancer;
  • Be able to discriminate between clinically useful and less clinically useful breast cancer susceptibility gene tests;
  • Be informed of new approaches to management of hereditary prostate cancer risk;
  • Describe state of the art approaches to the management of individuals with inherited mutations;
  • Apply cutting edge science to treat breast and/or ovarian cancer patients who have inherited mutations;
  • Identify and understand prevention and early diagnostic strategies for individuals at risk for hereditary breast cancer;
  • Compare and contrast BRCA management models in countries with different health resources and priorities;
  • Identify issues and elaborate priorities for hereditary breast, ovarian and pancreas cancer basic science and clinical research;
  • Fully consider ethical issues surrounding population testing for breast and ovarian cancer risk;
  • Better understand the factors influencing risk communication among families carrying a BRCA mutation.